Review decision: November 2015
We checked this guideline and decided that it should be updated. For details, see the update decision, decision matrix and the process for deciding if an update is needed. Details of the update will be available on the guidelines in development webpage in due course. No further checks of this guideline will be scheduled until this update is published.
The advice in this guideline covers:
- some of the tests and treatments that patients with early and locally advanced breast cancer should be offered, in particular:
– reducing the amount of surgery under your arm
– breast reconstruction when breast conservation is not possible
– chemotherapy and endocrine treatments
– biological treatments.
It does not specifically look at:
- the care of patients with advanced breast cancer or those with rare or non-cancerous tumours of the breast
- the care of people who do not have breast cancer themselves but have a family history of the disease.
The NICE guideline on advanced breast cancer has been updated. It includes recommendations on exercise for people with or at risk of breast-cancer-related lymphoedema, and these are also relevant for people with early or locally advanced breast cancer. They can be found in section 1.5 of the guideline.
This guideline updates the following technology appraisals:
- TA107 Breast cancer (early) - trastuzumab (published August 2006)
- TA108 Breast cancer (early) - paclitaxel (published September 2006)
- TA109 Breast cancer (early) - docetaxel (published September 2006).
NICE and the Department of Health are currently reviewing the future position on updating technology appraisals within clinical guidelines, with particular reference to implications for the funding direction on technology appraisals. In the meantime, the technology appraisal guidance remains available and should continue to be followed. The statutory funding direction remains in place for the recommendations contained in the technology appraisal guidance.